CRISPR might have taken the world by storm but what’s next for gene editing technology? Ashley Jacobi, senior staff scientist at Integrated DNA Technologies (IDT) examines what's next.
Panna Sharma, CEO of clinical stage oncology biotech Lantern Pharma, speaks to EPM about how his company’s artificial intelligence platform could help revolutionise drug development and ultimately change the way we treat cancer.
The world’s leading practitioners in genomics are now shaping a community of experts in Manchester. Health writer and Guardian contributor, Rachel Pugh, investigates the opportunities for local patients and international investors alike.
The rise of artificial intelligence has been popular within the life sciences industry and in particular pharma. Find out why and what it means for the future of drug development.
With the high costs of drug discovery, Tyler Golato, scientific lead at Molecule, discusses why new business models are needed if innovation is to continue.
Dr Nicholas Jones and Elizabeth Swan, patent attorneys at European intellectual firm Withers & Rogers, explain why pharma companies may be missing out on opportunities to repurpose existing drugs.
Antimicrobial resistance (AMR) is one of the biggest threats facing the world but arguably not enough is being done by both pharma companies and governments around the world.
Dr David Lewis, director of aerosol research at pharmaceutical company Chiesi, discusses how the company is focusing on new technologies to advance drug discvoery and future-proof innovation.
Stephen Tindal, director of science and technology at Catalent Pharma Solutions discusses what methods can be used to classify a drug’s solubility and bridge the divide between disciplines during development phases.
